{
    "clinical_study": {
        "@rank": "164699", 
        "acronym": "CC-01", 
        "arm_group": [
            {
                "arm_group_label": "Adjuvant Chemotherapy (Arm A)", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3.  Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary."
            }, 
            {
                "arm_group_label": "Concurrent radiochemotherapy, CCRT (Arm B)", 
                "arm_group_type": "Active Comparator", 
                "description": "Pelvic RT is delivered using IMRT technique, 45\uff5e50.4 Gy/4\uff5e7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant\n      chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival\n      (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical\n      cancer patients with risk factors."
        }, 
        "brief_title": "A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Uterine Cervical Neoplasms", 
            "Cervical Cancer", 
            "Uterine Cervical Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  FIGO stage: \u2160B\uff5e\u2161A, cervical cancer;\n\n          -  Age\u226460 years; female, Chinese women;\n\n          -  Initial treatment is radical hysterectomy + pelvic lymph node dissection;\n\n          -  Pathological diagnosis: cervical squamous cell invasive carcinoma;\n\n          -  Pathologic examination and meet the following one of the indications of adjuvant\n             therapy: \u2460 lymph node metastasis, \u2461 parametrial invasion, \u2462 \u2265 2/3 deep stromal\n             invasion, \u2463 histopathological grading in poorly differentiated (G2 to G3), \u2464\n             lymphatic vascular space involvement, \u2465 tumor diameter> 4cm;\n\n          -  Laboratory tests: WBC\u22654\u00d710(9)/L, NEU\u22652\u00d710(9)/L, PLT\u226580\u00d710(9)/L, serum bilirubin\u2264 1.5\n             times the upper limit of normal, transaminase\u2264 1.5 times the upper limit of normal,\n             BUN, Cr\u2264 normal\n\n          -  Performance status: Karnofsky score\u226560;\n\n          -  No prior treatment;\n\n          -  Receiving extensive resection of uterus (type III) plus pelvic lymph nodes wide\n             resection; pathologically diagnosed with cervical squamous cell carcinoma;\n\n          -  Provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  With severe or uncontrolled internal disease, unable to receive surgery and/or\n             unsuitable for radiotherapy or chemotherapy\n\n          -  History of organ transplantation, immune diseases;\n\n          -  History of serious mental illness, a history of brain dysfunction;\n\n          -  Drug abuse or a history of drug abuse;\n\n          -  Suffering from other malignancies;\n\n          -  Concurrently participating in other clinical trials\n\n          -  Unable or unwilling to sign informed consents;\n\n          -  Unable or unwilling to abide by protocol."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755897", 
            "org_study_id": "2012-GYN/CC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Adjuvant Chemotherapy (Arm A)", 
                    "Concurrent radiochemotherapy, CCRT (Arm B)"
                ], 
                "intervention_name": "radical hysterectomy + pelvic lymph node dissection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Adjuvant Chemotherapy (Arm A)", 
                "description": "135-175 mg/m(2) intravenously (IV) on day 1", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Adjuvant Chemotherapy (Arm A)", 
                "description": "75 mg/m(2) IV on day 2 and 3", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Concurrent radiochemotherapy, CCRT (Arm B)", 
                "description": "35 mg/m(2) IV once a week", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Concurrent radiochemotherapy, CCRT (Arm B)", 
                "description": "IMRT", 
                "intervention_name": "Pelvic RT", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 21, 2013", 
        "location": [
            {
                "contact": {
                    "email": "weng.dh@gmail.com", 
                    "last_name": "Danhui Weng, MD", 
                    "phone": "+862783662681"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430030"
                    }, 
                    "name": "Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology"
                }, 
                "investigator": {
                    "last_name": "Hui Wang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "baoxiacui@hotmail.com", 
                    "last_name": "Baoxia Cui, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250012"
                    }, 
                    "name": "Qilu Hospital, Shandong University"
                }, 
                "investigator": {
                    "last_name": "Baoxia Cui, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zhuchangkun@zju.edu.cn", 
                    "last_name": "Changkun Zhu, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310006"
                    }, 
                    "name": "Women's Hospital, School of Medicine, Zhejiang University"
                }, 
                "investigator": {
                    "last_name": "Changkun Zhu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients", 
        "overall_contact": {
            "email": "weng.dh@gmail.com", 
            "last_name": "Danhui Weng, MD", 
            "phone": "+862783662681"
        }, 
        "overall_official": {
            "affiliation": "Huazhong University of Science and Technology", 
            "last_name": "Ding Ma, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DFS was definite as the time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence.", 
            "measure": "disease-free survival (DFS) of the adjuvant chemotherapy arm (arm A)", 
            "safety_issue": "No", 
            "time_frame": "up to 3-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755897"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Huazhong University of Science and Technology", 
            "investigator_full_name": "Ding Ma", 
            "investigator_title": "Director of Department of Gynecology and Obstetrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "DFS of the adjuvant CCRT arm (arm B)", 
                "safety_issue": "No", 
                "time_frame": "1-year DFS and 3-year DFS"
            }, 
            {
                "measure": "3-year overall survivals (OS) of the arm A and the arm B", 
                "safety_issue": "No", 
                "time_frame": "3-year"
            }, 
            {
                "measure": "Quality of Life in two arms", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "chemotherapy- and radiotherapy- related adverse effects respectively in two arms", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Huazhong University of Science and Technology", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Huazhong University of Science and Technology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}